Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

MAPT-protokol: Fixering versus artroplastik kirurgiske behandlinger for tidlig genopretning efter hoftefraktur (FASTER-HIP) (FASTER-HIP)

5. november 2026 opdateret af: Joseph Patterson, University of Southern California

Musculoskeletal Adaptiv Platformforsøg (MAPT): Fastgørelse Versus Artroplastik Kirurgiske Behandlinger for Tidlig Genopretning Efter Hoftebrud (FASTER-HIP)

This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.

Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.

FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

600

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Ottawa, Canada, K1H 8L6
        • Ikke rekrutterer endnu
        • The Ottawa Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Bradley Meulenkamp, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z4
        • Rekruttering
        • University of British Columbia
        • Kontakt:
          • Aresh Sepehri, MD
        • Kontakt:
        • Ledende efterforsker:
          • Aresh Sephri, MD
      • Vancouver, British Columbia, Canada
        • Rekruttering
        • Fraser Health Authority
        • Kontakt:
        • Kontakt:
          • Telefonnummer: 604-777-5577
        • Ledende efterforsker:
          • Darius Viskontas, MD
    • Ontario
      • London, Ontario, Canada, N6A 5W9,
        • Rekruttering
        • London Health Sciences Centre
        • Kontakt:
        • Ledende efterforsker:
          • Emil Schemitsch, MD
      • Edinburgh, Det Forenede Kongerige, EH8 8BG
    • California
      • Irvine, California, Forenede Stater, 92660
        • Rekruttering
        • University of California, Irvine
        • Ledende efterforsker:
          • Gerard Slobogean, MD
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Ledende efterforsker:
          • Carol Lin, MD
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • University of Southern California
        • Ledende efterforsker:
          • Joshua L Gary, MD
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Los Angeles General Medical Center
        • Ledende efterforsker:
          • Joshua L Gary, MD
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California San Francisco
        • Ledende efterforsker:
          • Saam Morshed, MD
        • Kontakt:
    • Florida
      • Miami, Florida, Forenede Stater, 33146
        • Ikke rekrutterer endnu
        • University of Miami
        • Kontakt:
        • Ledende efterforsker:
          • Giselle Hernandez, MD
    • Indiana
      • Bloomington, Indiana, Forenede Stater, 47405
        • Rekruttering
        • Indiana University
        • Ledende efterforsker:
          • Dillon O'Neill, MD
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
        • Ledende efterforsker:
          • Mark Gage, MD
        • Kontakt:
      • Largo, Maryland, Forenede Stater, 20774
        • Rekruttering
        • University of Maryland Capital Region Health
        • Ledende efterforsker:
          • Todd Jaeblon, MD
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Ikke rekrutterer endnu
        • Beth Israel Deaconess Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Ishaq Ibrahim, MD
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Massachusetts General Brigham
        • Kontakt:
        • Ledende efterforsker:
          • Michael Weaver, MD
    • Mississippi
      • University, Mississippi, Forenede Stater, 38677
        • Rekruttering
        • University of Mississippi
        • Ledende efterforsker:
          • Patrick Bergin, MD
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10016
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45221
        • Rekruttering
        • University of Cincinnati
        • Kontakt:
        • Ledende efterforsker:
          • Michael Beltran, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Ledende efterforsker:
          • Brandon Hull, MD
        • Kontakt:
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18102
        • Rekruttering
        • St. Luke's University Health System
        • Ledende efterforsker:
          • Dustin Greenhill, MD
        • Kontakt:
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29601
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37235
        • Rekruttering
        • Vanderbilt University
        • Kontakt:
        • Ledende efterforsker:
          • Lauren Tatman, MD
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84108
        • Rekruttering
        • University of Utah
        • Ledende efterforsker:
          • Lucas Marchand, MD
        • Kontakt:
    • Vermont
      • Burlington, Vermont, Forenede Stater, 05405
        • Ikke rekrutterer endnu
        • University of Vermont
        • Kontakt:
        • Ledende efterforsker:
          • Michael Blankstein, MD
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • Inova Health Care Services
        • Ledende efterforsker:
          • Greg Gaski, MD
        • Kontakt:
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53706
        • Rekruttering
        • University of Wisconsin - Madison
        • Ledende efterforsker:
          • Chris Domes, MD
        • Kontakt:
      • Grålum, Norge, 1714
        • Rekruttering
        • Sykehuset Østfold HF / Østfold Hospital Trust
        • Kontakt:
          • Frede Frihagen, MD
        • Kontakt:
        • Ledende efterforsker:
          • Frede Frihagen, MD
      • Barcelona, Spanien
        • Ikke rekrutterer endnu
        • Hospital Universitari Vall d'Hebron
        • Kontakt:
        • Ledende efterforsker:
          • Carlos Alberto Piedra-Calle, MD
      • Barcelona, Spanien
        • Ikke rekrutterer endnu
        • Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
        • Ledende efterforsker:
          • Alfred Dealbert, MD
        • Kontakt:
      • Barcelona, Spanien, 08221
        • Ikke rekrutterer endnu
        • Hospital Universitario Mutua de Terrassa
        • Kontakt:
        • Ledende efterforsker:
          • Pablo Castillon Bernal, MD
      • Barcelona, Spanien
        • Ikke rekrutterer endnu
        • FRCB-IDIBAPS (Hospital Clinic Barcelona)
        • Kontakt:
        • Ledende efterforsker:
          • Pilar Camacho, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

60 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
  • The patient has a health condition affecting physical mobility.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism.
  • Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.

Exclusion Criteria:

  • The patient is not clinically suitable for either compared treatment.
  • Expected injury survival of less than 12 months.
  • Terminal illness with expected survival of less than 12 months.
  • Incarceration.
  • Unable to obtain informed consent due to language barriers.
  • Unable to obtain informed consent because the legally authorized representative was unavailable.
  • Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study or intervention domain that does not permit co-enrollment.
  • Prior enrollment in the specific platform trial intervention domain.
  • Patient or legally authorized representative did not provide informed consent (declined participation).
  • Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
  • Other reasons to exclude the patient, as approved by the data coordinating center.
  • Associated lower extremity injury that prevents post-operative weight-bearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Injury did not occur within 21 days of screening.
  • Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Hoftealloplastik

Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.

Aktiv komparator: Intern fiksering

Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite outcome of death, ambulation status, and days alive and out of hospital.
Tidsramme: 120 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days after randomization

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite outcome of death, ambulation status, and days alive and out of hospital.
Tidsramme: 365 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
365 days after randomization
Death
Tidsramme: 120 days post-randomization

Death consists of time to all-cause mortality.

120 days post-randomization
Death
Tidsramme: 12 months post-randomization

Death consists of time to all-cause mortality.

12 months post-randomization
Ambulation status
Tidsramme: 120 days post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

120 days post-randomization
Ambulation status
Tidsramme: 12 months post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

12 months post-randomization
Days alive and out of hospital
Tidsramme: 120 days post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days post-randomization
Days alive and out of hospital
Tidsramme: 12 months post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
12 months post-randomization
Health-related quality of life
Tidsramme: 120 days days post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

120 days days post-randomization
Health-related quality of life
Tidsramme: 12 months post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

12 months post-randomization
Numeric Pain Rating Scale
Tidsramme: During hospitalization in the first seven postoperative days

The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain

During hospitalization in the first seven postoperative days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Joseph T Patterson, MD, University of Southern California

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. januar 2026

Primær færdiggørelse (Anslået)

28. februar 2029

Studieafslutning (Anslået)

31. januar 2030

Datoer for studieregistrering

Først indsendt

31. oktober 2025

Først indsendt, der opfyldte QC-kriterier

19. november 2025

Først opslået (Faktiske)

24. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner